PharmiWeb Recruiter Blog

• State-of-the-Art Platform Comprised of Established and Emerging Technologies Across a Wide Spectrum of RNA Discovery, Development and Delivery, Excluding RNAi Therapeutics
• Strategic Partnership with Beam Therapeutics Provides Access to Beam’s RNA and Delivery Technologies for Multiple Therapeutics Applications
• Founding and Leadership Teams Comprised of Recognized Scientific Pioneers, Successful Drug Developers and Accomplished Biopharma Executives
•  Initial Funding Led by ARCH Venture Partners with Participation from a16z Bio + Health and Newpath Partners

CAMBRIDGE, Mass. – September 7, 2022 – Orbital Therapeutics launched today with a vision of enhancing global health by unleashing the full potential of RNA medicines to treat human disease in ways that were not previously possible.

COPENHAGEN, Denmark, September 6, 2022 – BioInnovation Institute (BII), an international commercial non-profit foundation incubating and accelerating world-class life science research, today announces the latest cohort of participants in its Venture Lab acceleration program for early-stage companies. The cohort consists of nine ventures plus two corporate-sponsored innovation projects from Novo Nordisk – all strategically aligned with BII’s focus on developing ground-breaking scientific initiatives for the benefit of human and planetary health.

Epredia, a global leader in precision cancer diagnostics, today announced that its parent company PHC Holdings Corporation [TSE 6523] has acquired anatomical pathology suppliers Microm Microtech France (MMFrance) and Laurypath in a strategic expansion of Epredia’s presence in Europe.

Bagsværd, Denmark and Watertown, Mass, US , 01 September 2022 – Novo Nordisk and Forma Therapeutics, Holdings Inc. (Nasdaq: FMTX) today announced that they have entered into a definitive agreement under which Novo Nordisk will acquire Forma Therapeutics for USD 20 per share in cash, which represents a total equity value of USD 1.1bn. Forma Therapeutics is a clinical-stage biopharmaceutical company focused on transforming the lives of patients with sickle cell disease (SCD) and rare blood disorders.

XNK Therapeutics AB (“XNK”) today announced the successful completion of the building phase of the company’s new GMP clean room facility.

Egham, UK - 25 August 2022 - Essential Pharma, an international speciality pharma group focused on maintaining access to well-established, “at risk” products essential to patients across multiple therapeutic areas, announces the strengthening of its operating platform to support the next phase of its growth, with the granting of new establishment and manufacturing licences in Switzerland and Malta.

Transaction Expands Labcorp’s Footprint with New Jersey’s leading academic health system

Cambridge, UK, 22 August 2022: Chesterford Research Park has announced that Constructive Bio has joined the Park’s highly regarded multi-occupier R&D building, Science Village.

One of the largest manufacturing sites for the company, the $105 million facility adds capacity to enable more life-saving vaccines and therapies

NEW YORK--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE:BMY) announced today that it has successfully completed its acquisition of Turning Point Therapeutics, Inc. (“Turning Point”), in an all-cash transaction. With the completion of the acquisition, Turning Point shares have ceased trading on the NASDAQ Global Select Market and Turning Point is now a wholly owned subsidiary of Bristol Myers Squibb.